Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

作者：Fernandez Rozadilla C; Cazier J B; Moreno V; Crous Bou M; Guino E; Duran G; Lamas M J; Lopez R; Candamio S; Gallardo E; Pare L; Baiget M; Paez D; Lopez Fernandez L A; Cortejoso L; Garcia M I; Bujanda L; Gonzalez D; Gonzalo V; Rodrigo L; Rene J M; Jover R; Brea Fernandez A; Andreu M; Bessa X; Llor X; Xicola R; Palles C; Tomlinson I; Castellvi Bel S; Castells A; Ruiz Ponte C; Carracedo A^*

来源：The Pharmacogenomics Journal, 2013, 13(3): 209-217.

DOI：10.1038/tpj.2012.2

• ADR
• colorectal cancer
• FOLFOX
• GWAS
• 5-fluorouracil

The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale.

• 出版日期2013-6
• 单位河北医科大学